Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.66 Analyst target: $11.50 Upside: 592.77%
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of precision cancer medicines. The company is headquartered in Watertown, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.